FDA Approved LEQEMBI on 2023 and
China NMPA Approved LEQEMBI
on 2024
Leqembi (lecanemab) is a monoclonal antibody that has shown
promise in the treatment of Alzheimer's disease.
Leqembi (lecanemab) is a monoclonal antibody that has shown
promise in the treatment of Alzheimer's disease.
We are a Hong Kong based organization aims to facilitate the patient to use a reasonable price to access the most advanced biologics.
From 2019, China government make a significant changes to centralize all medication procurement to control drug prices, and become the biggest lobbying power to the pharmaceutical companies, and that’s why China government can get the lowest cost of branded medication worldwide.
Annual price based on 10mg/kg IV biweekly dosage
per year
per half year
Reference price in US:
USD 26,500 per year
Here is the usual steps you need to follow.
Confirm you are the RIGHT patient to use this medications, please click HERE to fill the information
Provide the medication information, including the lot number, expiry date, photo of the medication.
Online consultation to doctors to confirm the needs.
Deposit the first medication fee (30%)
Tailor made the itinerary for pick up location in Shenzhen.
Deposit the second medication fee 7 days prior to arrival (40%)
Settle the balance on-site.
Our team is always here to help. Send us a message and we'll get back to you shortly.